ELAVAY 2025 BENCHMARK REPORT
The Future of Advocacy is Measurable. This Report Proves It.
The 2025 ELAVAY Advocacy Intelligence Benchmark Report analyzes how 70+ pharma, biotech, and med device companies are transforming patient engagement into strategic business impact.
Access the report through a confidential strategy briefing.
If Advocacy doesn’t drive access, it won’t survive the next budget cycle.
- Your team builds trust, but leadership still asks for ROI.
- You’re influencing patients, but can’t influence the product roadmap.
- Your insights are real—but they’re not driving decisions.
The missing piece?
A system to track, benchmark, and evolve Advocacy as a core function of commercial success.
ABOUT THE REPORT
How 70+ Industry Leaders Are Reframing Advocacy as Market Intelligence
This is not a whitepaper.
It’s the most comprehensive analysis of how Advocacy teams shape market readiness, access, and trust — from preclinical to post-launch.
This is the playbook used by teams who win early, not react late.
What’s Inside:
- The Advocacy Implementation Index™ — ELAVAY’s proprietary framework to assess your team’s strategic maturity
- Data-backed benchmarks across 70+ companies diving into over 20 different disease states
- Real-world examples of how top-performing teams secure internal buy-in
- Best practices for aligning with access, commercial, and policy leaders
- A new language to frame Advocacy in executive conversations
PROOF + AUTHORITY
Already in Use by Leading Advocacy & Engagement Teams
Advocacy leaders across oncology, rare disease, immunology, and neuroscience are using the ELAVAY Benchmark Report to:
- Shape early-stage strategy
- Align Advocacy with Access, HEOR, and Policy
- Strengthen the case for long-term investment
- Become institutional stakeholders—not just storytellers
Social Proof Strip
Trusted by patient advocacy teams at…
It’s the first time our Advocacy team was seen as a driver of launch success—not just patient experience.
STRATEGY BRIEFING FORM
Let’s Talk About Where You Stand
To ensure alignment and context, access to the report is available through a 1:1 strategy briefing with the ELAVAY team.
STICKY CTA / CLOSER
The most strategic teams in pharma are already using Advocacy Intelligence.